Vollständiger Abstract
Worum geht es in dieser Arbeit?
Abstract G‐protein–coupled receptor class C group 5 member D (GPRC5D) has emerged as a crucial immunotherapy target in relapsed/refractory multiple myeloma. Although the T‐cell‐engaging bispecific antibody talquetamab is currently the only approved anti‐GPRC5D therapy, numerous promising agents are undergoing clinical evaluation. While anti‐GPRC5D chimeric antigen receptor T cells show potential, this review focuses specifically on T‐cell‐engaging bispecific and trispecific antibodies. We highlight how GPRC5D differs clinically from B‐cell maturation antigen, explore mechanisms of resistance, discuss novel therapeutic strategies including combination regimens and talquetamab as bridging therapy to chimeric antigen receptor T cells, and review key investigational T‐cell engagers currently in development.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Darren Pan, Anupama Kumar, Jodi J. Lipof, Alfred Chung, Jeffrey L. Wolf, Thomas G. Martin, Shagun Arora, Peter H. Sayre, Ajai Chari
- Quelle
- Cancer
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0008-543X, 1097-0142
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Darren Pan, Anupama Kumar, Jodi J. Lipof, Alfred Chung, Jeffrey L. Wolf, Thomas G. Martin, Shagun Arora, Peter H. Sayre, Ajai Chari (2026). GPRC5D‐targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies. Cancer. https://doi.org/10.1002/cncr.70597
Kontext